CD47 is a potent Don’t eat me signal that enables cancer cells to evade immune surveillance and killing by innate immune cells, such as macrophages.

By using bispecific antibodies with a high affinity targeting arm (against a tumor-associated antigen, or TAA) and an anti CD47 arm of an optimized low affinity, the Don’t eat me signal is blocked selectively on TAA-positive cells, leading to the effective engulfment and degradation of tumor cells by macrophages (left-hand part of the video).

Due to the absence of a tumor-specific targeting arm, a monovalent anti CD47 bsAb is unable to bind and block CD47, with tumor cells that can resist the attack of macrophages (right-hand part of the video).

Images were taken with Nanolive’s 3D Cell Explorer at a rate of one image every 30 seconds.

For more information on fully human CD47-blocking κλ-bodies, please visit Light Chain Bioscience.

Download our Application Note

Read our latest news

Newsletter August 2024: Lipid droplets, a window into cellular metabolism and dysfunction

Aug 21, 2024 | News

Welcome to the August edition of the AI for Live Cell Insights Newsletter, bringing you the latest live cell analyses powering drug discovery and cosmetics development. Each month, we will explore a new application of AI-based cellular analysis for label-free live...

Newsletter July 2024: Anti-aging cosmetics and zombie cells

Jul 16, 2024 | News

Welcome to the July edition of the AI for Live Cell Insights Newsletter, bringing you the latest live cell analyses powering drug discovery and cosmetics development. Each month, we will explore a new application of AI-based cellular analysis for label-free live cell...

Cytotoxic Drug Development Application Note

Jul 15, 2024 | News

Discover how Nanolive’s LIVE Cytotoxicity Assay transforms cytotoxic drug development through high-resolution, label-free quantification of cell health and death. Our application note explores how this advanced technology enables real-time monitoring of cell death...

More news